Prosecution Insights
Last updated: April 19, 2026
Application No. 18/039,917

AMILORIDE DERIVATIVES AND METHODS OF USING SAME FOR THE TREATMENT OF VIRAL INFECTIONS

Non-Final OA §101§102§112
Filed
Jun 01, 2023
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rutgers The State University Of New Jersey
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
2y 2m
To Grant
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
690 granted / 951 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
32 currently pending
Career history
983
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
20.1%
-19.9% vs TC avg
§102
34.4%
-5.6% vs TC avg
§112
23.5%
-16.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 951 resolved cases

Office Action

§101 §102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on November 21, 2025. Application No. 18/039,917, is a 371 of PCT/US21/61774, filed December 3, 2021, and claims the benefit of U.S. Provisional application No. 63/120,912, filed December 3, 2020. Claims 1-20 are pending. Election/Restrictions Applicant’s elections without traverse of the invention of Group I and the compound species of DMA-132, in the reply filed on November 21, 2025, are acknowledged. Claims 9-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claims 6 and 7 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. The election were made without traverse in the reply filed on November 21, 2025. Claims 1-5, 8, and 16-20 are examined below. Please note: the method claims, claims 9-15, are currently withdrawn. Upon finding allowable subject matter in the elected invention these claims will be rejoined. However, these claims including “the prevention” or “preventing” viral infection. Prevention is not enabled by the present disclosure and these claims will be rejected under 35 USC 112(a) upon rejoinder, accordingly. It is suggested that applicant amend these method claims to cancel “the prevention” or “preventing” in response to this Office action to move the claims closer to allowance. Non-Statutory Use Claims Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 16-20 rejected under 35 U.S.C. 101 because the claimed invention is not supported by either an asserted utility or a well-established utility. See MPEP 2173.05(q), “Use” Claims. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 16-20 are rejected under 35 U.S.C. 112(b), as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. See MPEP 2173.05(q), “Use” Claims. Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5, and 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Cragoe et al., U.S. Patent No. 3,313,813. Citing the CAS abstract for Cragoe, Cragoe discloses the elected species DMA-132, as follows: PNG media_image1.png 261 441 media_image1.png Greyscale , (Cragoe et al., citing the CAS Abstract for the compound depicted above; see Cragoe et al., ‘813 patent, Col. 3, lns. 25-35, for pharmaceutical compositions of the compounds disclosed therein). This compound reads on the elected species. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached on Monday - Friday, 9:00 a.m. -5:00 p.m.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Jun 01, 2023
Application Filed
Dec 15, 2023
Response after Non-Final Action
Dec 18, 2025
Non-Final Rejection — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594259
TREATMENT REGIMEN FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR CONDITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595264
HETEROCYCLIC GLP-1 AGONISTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595255
HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12577204
A SOLUTION OF TEMPO-DERIVATIVES FOR USE AS ELECTROLYTE IN REDOX-FLOW CELLS
2y 5m to grant Granted Mar 17, 2026
Patent 12577205
HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 2m
Median Time to Grant
Low
PTA Risk
Based on 951 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month